West Fraser Timber Co. Ltd. (WFG)
NYSE: WFG · Real-Time Price · USD
69.80
+0.49 (0.71%)
Aug 1, 2025, 4:00 PM - Market closed
Verve Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Verve Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $102.75, which forecasts a 47.21% increase in the stock price over the next year. The lowest target is $96 and the highest is $115.
Price Target: $102.75 (+47.21%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Verve Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Securities | TD Securities | Strong Buy Maintains $98 → $96 | Strong Buy | Maintains | $98 → $96 | +37.54% | Jul 25, 2025 |
| TD Securities | TD Securities | Strong Buy Maintains $99 → $98 | Strong Buy | Maintains | $99 → $98 | +40.40% | Jul 24, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $109 → $100 | Buy | Maintains | $109 → $100 | +43.27% | Feb 18, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $120 → $109 | Buy | Maintains | $120 → $109 | +56.16% | Feb 3, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $100 → $120 | Buy | Maintains | $100 → $120 | +71.92% | Oct 25, 2024 |
Financial Forecast
Revenue This Year
6.02B
from 6.17B
Decreased by -2.51%
Revenue Next Year
6.59B
from 6.02B
Increased by 9.54%
EPS This Year
4.18
from -0.07
EPS Next Year
7.63
from 4.18
Increased by 82.71%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.7B | 7.3B | 7.5B | ||
| Avg | 6.0B | 6.6B | 6.8B | ||
| Low | 5.6B | 5.8B | 6.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.5% | 21.7% | 14.4% | ||
| Avg | -2.5% | 9.5% | 2.8% | ||
| Low | -8.7% | -4.3% | -5.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.36 | 8.87 | 9.72 | ||
| Avg | 4.18 | 7.63 | 9.35 | ||
| Low | 4.04 | 6.53 | 9.07 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 112.4% | 27.4% | ||
| Avg | - | 82.7% | 22.6% | ||
| Low | - | 56.3% | 18.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.